胃肠道间质瘤及其辅助治疗研究进展

Gastrointestinal stromal tumor and its adjuvant therapy

胃肠道间质瘤是来源于胃肠道Cajal细胞的肿瘤,目前中国的发病率约为每年1.5～1.7/10万人。2002年甲磺酸伊马替尼在该领域的上市明显改变了该疾病的自然预后,将晚期胃肠道间质瘤患者的总生存期提高了近2倍。2009年Z9001研究又揭示了伊马替尼在完整切除后的胃肠道间质瘤的辅助治疗的重要性,其明显延长了术后患者的无进展生存时间,降低复发风险达65%。然而,在伊马替尼的辅助治疗领域,仍有很多尚未解决的问题需要进一步研究。

Gastrointestinal stromal tumor（GIST） originates from the gastrointestinal Cajal cell and its incidence in China is around 1.5～1.7/100 000 per year.In 2002,the introduction of imatinib mesylate radically changed the natural history of the disease,increasing the overall survival（OS） for GIST patients by about 2 times.In 2009,Z9001 study revealed the importance of imatinib adjuvant therapy in GIST patients after the complete resection of the primary tumor.After tumor resection,the median progression free survival was significantly improved and the risk of recurrence was reduced by 65%.However,there are still many questions concerning imatinib adjuvant therapy to be answered.